Get the Stockscreener App
1.55
2.52%
-0.04
Acurx Pharmaceuticals Inc stock is traded at $1.55, with a volume of 32,524.
It is down -2.52% in the last 24 hours and up +0.65% over the past month.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
See More
Previous Close:
$1.59
Open:
$1.6
24h Volume:
32,524
Relative Volume:
0.29
Market Cap:
$6.66M
Revenue:
-
Net Income/Loss:
$-7.50M
P/E Ratio:
-0.352
EPS:
-4.4035
Net Cash Flow:
$-6.14M
1W Performance:
+3.33%
1M Performance:
+0.65%
6M Performance:
-41.51%
1Y Performance:
-82.74%
1-Day Range:
$1.5301
$1.61
1-Week Range:
$1.495
$1.88
52-Week Range:
$1.3259
$9.76
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
1.55 | 6.83M | 0 | -7.50M | -6.14M | -4.4035 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
Acurx Pharmaceuticals (ACXP) Registration filing Summary - Quartr
Acurx Pharmaceuticals (ACXP) upgraded to buy: Here's why - MSN
Acurx data: beneficial gut bacteria remain after repeated C. diff. courses - Stock Titan
Price to earnings forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Acurx Pharmaceuticals Inc. (ACXP) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update - Moomoo
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference - AOL.com
Acurx Pharmaceuticals outlines its antibiotic pipeline as investors weigh long-term prospects - ad-hoc-news.de
Acurx Pharmaceuticals (ACXP) Stock Analysis Report | Financials & Insights - Benzinga España
What date does Acurx Pharmaceuticals's (ACXP) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Clostridium Difficile Infections Market Forecast Signals - openPR.com
Price to book forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Enterprise value to EBITDA forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Price to book forward of Acurx Pharmaceuticals, Inc. – MUN:3ZO0 - TradingView
Enterprise value to EBITDA forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView
Price to earnings forward of Acurx Pharmaceuticals, Inc. – MUN:3ZO0 - TradingView
Price to earnings forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView
Acurx Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ACXP) - TradingView
ACXP Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView
Price to sales forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Acurx Pharmaceuticals Inc (ACXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enterprise value to revenue forward of Acurx Pharmaceuticals, Inc. – FWB:3ZO0 - TradingView
Acurx Pharmaceuticals (ACXP) Study update presentation Summary - Quartr
Enterprise value to EBIT forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Acurx Pharmaceuticals (ACXP) Holds Above Support After Modest GainParabolic SAR - DonanımHaber
Acurx Pharmaceuticals Inc (ACXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acurx Pharmaceuticals StockLong-term strategy and pipeline in focus - AD HOC NEWS
Acurx Pharmaceuticals Inc (ACXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Institutional Confidence - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Acurx presents research on ibezapolstat mechanism at Leiden conference - Investing.com UK
Inside Acurx’s 3.2Å look at a new antibiotic for drug‑resistant bacteria - Stock Titan
Certain Common Stock of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Warrants of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Stock Options of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
ACXP Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline Progress ContinuesEarnings Forecast Report - newsline.com
Acurx Pharmaceuticals (ACXP) Stock Slides Slightly as Price Tests SupportMcClellan Oscillator - newsline.com
ACXP Q1 2026 Earnings: Narrower-than-Expected Loss Delivers Positive SurpriseEarnings Trend Analysis - newsline.com
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why - Yahoo Finance
Acurx Pharmaceuticals stock (US00366D1037): Nasdaq price steady as investors eye valuation metrics - AD HOC NEWS
Acurx Pharmaceuticals (ACXP) Slides 5.08% as Support Level NearsBuyback Factor - DonanımHaber
Acurx Pharmaceuticals (ACXP) Declines 6.74% as Stock Nears Key Support at $1.71Rip Sell Trade - newsline.com
Acurx Pharmaceuticals stock (US00366D1037): Analyst consensus points to high upside from low Nasdaq - AD HOC NEWS
ACXPAcurx Pharmaceuticals Inc Latest SEC Filings - Finviz
ACXP Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Progress ContinuesDividend Growth Analysis - The Legal Advocate
ACXP Technical Analysis | Trend, Signals & Chart Patterns | ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) - ChartMill
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):